Understanding the molecular biology of cancer is crucial for developing targeted therapies and improving patient outcomes. This field explores how genetic and epigenetic changes drive cancer progression, offering fresh insights into treatment strategies. Below, we break down essential concepts with actionable takeaways for researchers and clinicians.
Cancer arises from mutations in key genes, such as oncogenes (e.g., RAS, MYC) and tumor suppressors (e.g., TP53, PTEN). These alterations disrupt normal cell signaling, leading to uncontrolled growth. Epigenetic changes—like DNA methylation and histone modifications—also play a role, often making cancer cells resistant to treatment.
Molecular biology reveals specific vulnerabilities in cancer cells. For example, BCR-ABL fusion proteins in chronic myeloid leukemia (CML) are targeted by tyrosine kinase inhibitors (TKIs) like imatinib. Similarly, HER2 amplification in breast cancer is treated with HER2-targeted antibodies. These therapies exploit molecular differences between cancer and healthy cells.
Recent advances include CAR-T cell therapy, which genetically engineers immune cells to attack cancer, and checkpoint inhibitors like pembrolizumab. Additionally, liquid biopsies—analyzing circulating tumor DNA—provide real-time monitoring of treatment response. These tools leverage molecular insights to tailor therapies precisely.
To stay current, researchers should focus on:
By focusing on these areas, scientists can advance precision oncology and improve patient care.
Tijolo cavista exterior vermelho — Azulejossola